Home
News
Create
Screeners
Insights
Vivanza Biosciences
2.
10
+0.10
(+5.00%)
Market Cap
₹8.40 Cr
PE Ratio
-50.00
Industry
Healthcare
Buy
Sell
Company Performance:
1D
+5.00%
1M
+15.38%
6M
+2.44%
1Y
-9.87%
5Y
-80.08%
View Company Insights
Latest news about Vivanza Biosciences
Vivanza Biosciences Limited Exempt from Annual Secretarial Compliance Report for FY26 Under SEBI Regulation 24A
10 days ago
Vivanza Biosciences Limited has informed BSE about its exemption from submitting the Annual Secretarial Compliance Report for FY26 under SEBI Regulation 24A. The company qualifies for exemption with paid-up share capital of Rs. 4 crore and net worth of Rs. 4,02,03,752.40, both falling below the regulatory thresholds of Rs. 10 crores and Rs. 25 crores respectively. This exemption is available under Regulation 15(2) of SEBI (LODR) Regulations, 2015, for smaller listed entities.
Vivanza Biosciences Files Non-Applicability Statement for SEBI LODR Regulation 32 Compliance
Apr 14, 2026
Vivanza Biosciences Limited Files Annual SEBI SAST Disclosure for FY26
Apr 09, 2026
Vivanza Biosciences Limited Confirms Non-Applicability of Large Corporate Status for FY26 Compliance
Apr 09, 2026
Vivanza Biosciences Submits SEBI Confirmation Certificate for Q4 FY26
Apr 07, 2026
More news about Vivanza Biosciences
17
Mar 26
Vivanza Biosciences Director Hemant Parikh Resigns Due to Personal Reasons
Vivanza Biosciences Limited formally announced the resignation of Mr. Hemant Amrish Parikh as Non-Executive Director, effective from close of business hours on March 17, 2026. The resignation was attributed to personal reasons with confirmation that no material concerns exist beyond those stated, ensuring full regulatory compliance under SEBI Listing Obligations.
18
Dec 25
Vivanza Biosciences Formalizes MOA Amendment for Packaging Business Expansion
Vivanza Biosciences has officially informed BSE about the approved amendment to its Memorandum of Association for expanding into plastic polymer films and packaging materials manufacturing. The company received overwhelming 99.90% shareholder approval through postal ballot, enabling diversification from biosciences into comprehensive packaging solutions including PE/PP bags, paper bags, and flexible packaging materials for various industries.
11
Nov 25
Vivanza Biosciences Reports Q2 Results, Appoints New Company Secretary, Plans Business Expansion
Vivanza Biosciences Limited announced key developments in its board meeting on November 11, 2025. The company reported Q2 FY2026 revenue of Rs. 373.18 lacs and profit before tax of Rs. 48.06 lacs. CS Chaitra Arora was appointed as the new Company Secretary and Compliance Officer, replacing CS Siddhi Shah who resigned. The board proposed expanding the business to include manufacturing of plastic polymer films, plastic bags, paper bags, and flexible packaging materials. A postal ballot process has been initiated for shareholder approval of the proposed changes to the Memorandum of Association.
28
Oct 25
Vivanza Biosciences Promoter Reduces Stake by 3.07% Through Market Transaction
Parth H. Parikh, a promoter of Vivanza Biosciences Limited, sold 12,28,781 shares (3.07% of total share capital) in an on-market transaction on October 29, 2024. This reduced his shareholding from 31.58% to 28.50%. The company's total equity share capital stands at 40,000,000 shares with a face value of Rs. 1 per share.
Vivanza Biosciences
2.
10
+
0.
10
(+
5.
00
%)
1 Year Returns:
-9.87%
Industry Peers
Sun Pharmaceutical
1,620.40
(-
3.
55
%)
Divis Laboratories
6,361.50
(-
0.
27
%)
Torrent Pharmaceuticals
4,117.20
(-
0.
72
%)
Dr Reddys Laboratories
1,317.10
(-
1.
04
%)
Lupin
2,296.10
(-
1.
93
%)
Cipla
1,295.00
(-
0.
83
%)
Mankind Pharma
2,267.40
(-
1.
11
%)
Zydus Life Science
927.40
(-
2.
00
%)
Aurobindo Pharma
1,413.80
(-
1.
50
%)
Glenmark Pharmaceuticals
2,299.50
(-
1.
52
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO